Anti-angiogenic therapies in prostate cancer

被引：6
|
作者：
Maria Martinez-Jabaloyas, Jose [1 ,2 ]
Antonio March-Villalba, Jose [1 ,2 ]
Mercedes Navarro-Garcia, Maria [1 ]
Dasi, Francisco [1 ,3 ]
机构：
[1] Univ Valencia, Inst Invest INCLIVA, Fdn Invest, Hosp Clin, E-46010 Valencia, Spain
[2] Univ Valencia, Hosp Clin, Urol Unit, E-46010 Valencia, Spain
[3] Univ Valencia, Sch Med, Dept Physiol, E-46010 Valencia, Spain
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2013年 / 13卷 / 01期
关键词：
angiogenesis; anti-angiogenic therapies; prostate cancer; review; CHALLENGES;
D O I：
10.1517/14712598.2013.733366
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Prostate cancer (PCa) is the second most common type of cancer among men in Western societies. Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.
引用
收藏
页码：1 / 5
页数：5
相关论文
共 50 条
  • [1] Anti-angiogenic therapies for gastric cancer
    Hironaka, Shuichi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 208 - 217
  • [2] Anti-Angiogenic Therapies for Children with Cancer
    Andre, N.
    Verschuur, A.
    Rossler, J.
    Sterba, J.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 879 - 889
  • [3] Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
    Haibe, Yolla
    Kreidieh, Malek
    El Hajj, Hiba
    Khalifeh, Ibrahim
    Mukherji, Deborah
    Temraz, Sally
    Shamseddine, Ali
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Angiogenesis and anti-angiogenic therapy in prostate cancer
    Mukherji, Deborah
    Temraz, Sally
    Wehbe, David
    Shamseddine, Ali
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) : 122 - 131
  • [5] Responses to anti-angiogenic therapies
    Paller, AS
    JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2000, 5 (01) : 83 - 86
  • [6] Nephrotoxicity of Anti-Angiogenic Therapies
    Van Wynsberghe, Margaux
    Flejeo, Joanne
    Sakhi, Hamza
    Ollero, Mario
    Sahali, Dil
    Izzedine, Hassan
    Henique, Carole
    DIAGNOSTICS, 2021, 11 (04)
  • [7] Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
    Raja, Fharat A.
    Hook, Jane M.
    Ledermann, Jonathan A.
    CANCER TREATMENT REVIEWS, 2012, 38 (06) : 662 - 672
  • [8] In pursuit of new anti-angiogenic therapies for cancer treatment
    Cai, Jun
    Han, Song
    Qing, Ruan
    Liao, Daiqing
    Law, Brian
    Boulton, Michael E.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 803 - 814
  • [9] Emerging immunologic approaches as cancer anti-angiogenic therapies
    Azimi, Mohammadreza
    Manavi, Mahdokht Sadat
    Afshinpour, Maral
    Khorram, Roya
    Vafadar, Reza
    Rezaei-Tazangi, Fatemeh
    Arabzadeh, Danyal
    Arabzadeh, Sattar
    Ebrahimi, Nasim
    Aref, Amir Reza
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [10] Anti-angiogenic therapies in cancer: achievements and open questions
    Ruegg, Curzio
    Mutter, Nicole
    BULLETIN DU CANCER, 2007, 94 (09) : 753 - 762
12345